Clinical research progress of ibrutinib in the treatment of chronic lymphocytic leukemia
Dongfeng Mao, Tao Wu, Hai Bai
Published 2019-07-15
Cite as Chin J Prim Med Pharm, 2019, 26(14): 1789-1792. DOI: 10.3760/cma.j.issn.1008-6706.2019.14.035
Abstract
Chronic lymphocytic leukemia(CLL) is a heterogeneous mature B lymphocytic tumor.The apoptosis of mature lymphocyte is inhibited and clonal proliferation of mature lymphocyte aggregates in blood, bone marrow, spleen and lymph nodes, resulting in a class of inert hematological tumors.At present, the clinical pathogenesis is not completely clear, environmental and occupational factors do not occupy a major position.Studies have shown that long-term exposure to low-frequency electromagnetic fields may be associated with its incidence, but patients with primary and secondary relatives of lymphatic malignancies increased incidence.Many families still have patients whose age is earlier and the disease is more serious.In recent years, with the continuous improvement of medical level, a variety of treatment methods for chronic lymphoblastic leukemia have emerged, including a variety of new drugs.Ibutinib is the world's first marketed Bruton's tyrosine kinase(BTK) inhibitor, for more patients with chronic lymphoblastic leukemia has brought the gospel.This article reviews the clinical research progress of ibrutinib in treating CLL.
Key words:
Ibrutinib; Leukemia, lymphocytic, chronic, B-cell; B-Lymphocytes; Tumor suppressor proteins; Rituximab; Fludarabine; Cyclophosphamide; Review
Contributor Information
Dongfeng Mao
Department of Hematology, Lanzhou General Hospital, Lanzhou Command, Lanzhou, Gansu 730050, China
Tao Wu
Hai Bai